Nobuhiko Kanaya
-
- CAR-T cell therapy research 8
- HER2/EGFR in Cancer Research 5
- Biotechnology top 10%
- Cancer Research and Treatments 12
-
- Virus-based gene therapy research 13
-
- Immunotherapy and Immune Responses 5
-
- Gastric Cancer Management and Outcomes 7
-
- Gastrointestinal Tumor Research and Treatment 6
-
- RNA Interference and Gene Delivery 5
- Co-authors
- Toshiyoshi FujiwaraShinji KurodaHiroshi TazawaShunsuke KagawaSatoru KikuchiYoshihiko KakiuchiMasahiko NishizakiTetsushi Kubota
- Cited by
- OncologyBiotechnologyGenetics
- Partner nations
- JapanUnited StatesNetherlands
In The Last Decade
Nobuhiko Kanaya
43 papers receiving 497 citations
Peers
Comparison fields: 5 of 53
- Oncology 232
- Biotechnology 69
- Genetics 148
- Immunology 94
- Pulmonary and Respiratory Medicine 123
Countries citing papers authored by Nobuhiko Kanaya
This map shows the geographic impact of Nobuhiko Kanaya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nobuhiko Kanaya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nobuhiko Kanaya more than expected).
Fields of papers citing papers by Nobuhiko Kanaya
This network shows the impact of papers produced by Nobuhiko Kanaya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nobuhiko Kanaya. The network helps show where Nobuhiko Kanaya may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Nobuhiko Kanaya, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 1 | |
| 5 | 2025 | 3 | |
| 6 | 2025 | 0 | |
| 7 | 2024 | 5 | |
| 8 | 2024 | 0 | |
| 9 | 2024 | 0 | |
| 10 | 2024 | 5 | |
| 11 | 2024 | 1 | |
| 12 | 2023 | 2 | |
| 13 | 2023 | 13 | |
| 14 | 2021 | 10 | |
| 15 | 2021 | 26 | |
| 16 | 2020 | 2 | |
| 17 | [Novel Therapeutic Strategy for Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer]. | 2017 | 3 |
| 18 | [A case of HER2-positive esophagogastric junction cancer treated by using a neoadjuvant chemotherapy regimen consisting of trastuzumab]. | 2014 | 3 |
| 19 | 2013 | 2 | |
| 20 | [Intraoperative delayed pneumothorax after subclavian vein catheterization]. | 1993 | 0 |
About Nobuhiko Kanaya
Nobuhiko Kanaya is a scholar working on Biotechnology, Gastroenterology and Oncology, having authored 57 papers that have together received 503 indexed citations. Recurring topics across this work include Virus-based gene therapy research (13 papers), Cancer Research and Treatments (12 papers), CAR-T cell therapy research (8 papers), Gastric Cancer Management and Outcomes (7 papers), Gastrointestinal Tumor Research and Treatment (6 papers), RNA Interference and Gene Delivery (5 papers), Immunotherapy and Immune Responses (5 papers) and HER2/EGFR in Cancer Research (5 papers). The work is most often cited by research in Oncology (232 citations), Biotechnology (69 citations) and Genetics (148 citations). Nobuhiko Kanaya has collaborated with scholars based in Japan, United States and Netherlands. Frequent co-authors include Toshiyoshi Fujiwara, Shinji Kuroda, Hiroshi Tazawa, Shunsuke Kagawa, Satoru Kikuchi, Yoshihiko Kakiuchi, Masahiko Nishizaki, Tetsushi Kubota, Yasuo Urata and Kazuhiro Noma.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.